Genoptix pockets $17.3M in early venture round

San Diego-based Genoptix has raised $17.3 million in a "series 1-D" round of venture capital. Genoptix provides laboratory services to hematologists and oncologists who are managing blood and bone marrow malignancies. Chicago Growth Partners joined existing investors Enterprise Partners, Alliance Technology Ventures, Tullis-Dickerson, U.S. Trust's Excelsior Venture Partners III, and Lotus Bioscience Investment Holdings in this round of financing.

- read this press release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.